Thermo Fisher Scientific (TMO) Q3 2025 10-Q Quarterly Report

Filed: Oct 31, 2025Period ending Sep 27, 2025

Health Care

Measuring & Controlling Devices, NECSEC EDGAR

Thermo Fisher Scientific (TMO) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 31, 2025 for the fiscal period ending Sep 27, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Thermo Fisher Scientific Q3 2025 10-Q Analysis

Management Discussion & Analysis

• Revenue $11,122M Q3 2025, up $524M YoY from $10,598M in Q3 2024
• GAAP operating margin 17.4% Q3 2025 vs 17.3% Q3 2024; Adjusted margin 23.3% vs 22.3%
• Best segment: Life Sciences Solutions revenue $2,588M (+8.4% YoY), margin 37.4% (+2.0 pts)
• Worst segment: Analytical Instruments margin 22.6% Q3 2025 vs 24.9% Q3 2024 (-2.3 pts) despite revenue growth
• Cash & equivalents down to $1.982B from $4.009B end of 2024; Operating cash flow $4.361B YTD, Free cash flow $3.319B YTD
• Management notes near-term headwinds in China and strategic investments impacting margins; expects 2025 adjusted tax rate ~10.5%

Risk Factors

• No material changes to risk factors since 2024 10-K filing

Thermo Fisher Scientific Q3 2025 Quarterly Financials
XBRL

Revenue

$11.1B

▲ +4.9% YoY▲ +2.5% QoQ

Net Income

$1.6B

▼ -0.9% YoY▼ -0.1% QoQ

Net Margin

14.5%

▼ -85bp YoY▼ -37bp QoQ

Source: XBRL data from Thermo Fisher Scientific Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Thermo Fisher Scientific

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.